AtoGen Co., Ltd. is a South Korean biotechnology company that specializes in the development of microbiome-modulatory novel drugs and functional food materials. Founded in 2010, the company focuses on leveraging cutting-edge genomic analysis technology and a self-built screening platform to create solutions that modulate the microbiome for improved health outcomes. AtoGen's research spans various health-related applications, including the prevention and treatment of diseases through innovative probiotic and postbiotic formulations.